![rapt therapeutics stock rapt therapeutics stock](https://s3.amazonaws.com/images.investorsobserver.com/ads/score-charts/bars/score-bar-chart-light-83.jpg)
RAPT Therapeutics (formerly FLX Bio) is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
Rapt therapeutics stock registration#
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Copies of the final prospectus relating to this offering may be obtained, when available, from: BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, by telephone at (800) 414-3627 or by e-mail at Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by email at or by telephone at (800) 326-5897 or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, by telephone at (888) 827-7275 or by email at Copies of the preliminary prospectus and, when available, the final prospectus related to the Offering are also available, or will be available, at A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on October 30, 2019. The offering is being made only by means of a prospectus. The shares are expected to begin trading on the Nasdaq Global Market on October 31, 2019, under the ticker symbol “RAPT.” The offering is expected to close on November 4, 2019, subject to the satisfaction of customary closing conditions.īMO Capital Markets, Wells Fargo Securities and UBS Investment Bank are acting as joint book-running managers for the offering. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by RAPT, are expected to be $36.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 450,000 shares of common stock at the initial public offering price, less the underwriting discount. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $12.00 per share. (NASDAQ: RAPT) Secures $143.SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE)-RAPT Therapeutics, Inc. InvestorNewsBreaks - RAPT Therapeutics Inc. RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress GlobeNewswire RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference GlobeNewswire
Rapt therapeutics stock trial#
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress GlobeNewswire
Rapt therapeutics stock skin#
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit GlobeNewswire RAPT Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors GlobeNewswire RAPT Therapeutics Reports Third Quarter 2021 Financial Results GlobeNewswire
![rapt therapeutics stock rapt therapeutics stock](https://drpgazette.com/wp-content/uploads/2021/06/Biotech-Sector-2-Chart-June-14-370x215.jpg)
More Company Releases for RAPT Therapeutics Inc. This worrisome indicator is a canary in the coal mine for stock-market tops MarketWatchīuy stocks now that the S&P 500 is finally charging out of its range MarketWatchĪs the S&P 500 falters, this is what it will take to revive the bull market MarketWatch RAPT Therapeutics started at overweight with $61 stock price target at J.P.